摘要
目的通过总结乳腺癌软脑膜转移(BCLM)在精准检测、生物标志物及治疗策略的最新研究进展,为BCLM患者的临床疗效和改善预后提供参考。方法围绕BCLM的分子诊断技术、预后生物标志物以及治疗策略展开研究,剖析BCLM的发生机制,分析当前诊断手段和治疗策略所面临的现存挑战。结果基于新型检测技术的进步,生物标志物指导下的个体化治疗策略展现出显著应用潜力;新型靶向药物与递送技术为改善患者预后提供新的治疗机遇。结论BCLM的临床管理应整合精准检测、生物标志物引导及多模式治疗策略,未来需进一步开展高质量临床研究以优化治疗体系,并提升患者生存期。
Objective To summarize the latest research advances in precision detection,biomarkers,and treatment strategies for breast cancer leptomeningeal metastasis(BCLM)in order to provide references for improving the clinical efficacy and prognosis of patients.Methods An in-depth analysis of the mechanisms underlying BCLM was conducted based on the molecular diagnostic techniques,prognostic biomarkers,as well as therapeutic strategies.Current challenges to diagnostic approaches and treatment strategies were also studied.Results Based on advancements in novel detection technologies,individualized treatment strategies guided by biomarkers promised wide applications.Furthermore,new targeted drugs and delivery technologies offered more opportunities to improve patients’prognosis.Conclusion The clinical management of BCLM should integrate precision testing,biomarker-guided approaches,and multimodal treatment strategies.High-quality clinical studies are essential to optimizing therapeutic frameworks and prolonging patients’survival.
作者
叶玲
徐蕊
阮聪
钱佳佳
胡伟琼
王祺茹
刘继勇
李纲
YE Ling;XU Rui;RUAN Cong;QIAN Jiajia;HU Weiqiong;WANG Qiru;LIU Jiyong;LI Gang(Department of Pharmacy,Fudan University Shanghai Cancer Center,Minhang,Shanghai 200240,China;Department of Pharmacy,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Oncology,Fudan University Shanghai Cancer Center,Minhang,Shanghai 200240,China)
出处
《中国药物警戒》
2026年第2期229-234,共6页
Chinese Journal of Pharmacovigilance
基金
上海市闵行区卫健委课题(2023MW35)
上海市闵行区卫健委课题(2022MW02)。
关键词
乳腺癌
软脑膜转移
诊断技术
生物标志物
治疗药物
Breast Cancer
Leptomeningeal Metastasis
Diagnostic Techniques
Biomarkers
Therapeutic Drugs
